The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study

I-Wei Chang; Chao-Tien Hsu; Jui-Wei Lin; Chih-Hsin Hung

doi:10.5114/fn.2013.39716

eISSN: 1509-572x
ISSN: 1641-4640

Folia Neuropathologica

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2013
vol. 51

Send email

Copy url:

abstract:

The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study

I-Wei Chang

,

Chao-Tien Hsu

,

Jui-Wei Lin

,

Chih-Hsin Hung

Folia Neuropathol 2013; 51 (4): 275-282

DOI: https://doi.org/10.5114/fn.2013.39716

Online publish date: 2013/12/24

View full text Get citation

PlumX metrics:

Ganglioglioma (GG) is an uncommon brain parenchymal neoplasm. Although most cases have indolent clinical behaviour, a subgroup of GGs does recur, especially in patients with unresectable disease. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that removes mutagenic and cytotoxic adducts from O6-guanine in DNA. Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents. Furthermore, MGMT promoter methylation has also been investigated as an independent favourable prognostic factor for glioblastoma. The primary management is surgical resection for GGs and gross total resection is recommended. Despite infrequent use of chemotherapy for low-grade GGs, it was still introduced to a subset of patients, especially those who had unresectable disease. We assessed clinicopathological features of nine cases of low-grade GG to further elucidate the relationship between the status of the MGMT protein expression and the prognosis. This series included four men and five women with a mean age of 21.6 years at the first surgery. The mean postoperative follow-up period was 6 years. Only two patients had recurrent disease after 1.7 and 3.2 years of the first surgery. Immunohistochemically, 11.1% exhibited 3+ nuclear staining for MGMT protein, 11.1% exhibited 2+ staining, 33.3% exhibited 1+ staining, and 44.4% exhibited 0 staining. Tumours with more intensive MGMT protein expression (2+~3+ immunostaining) tended to recur more frequently (p < 0.05), corresponding to the worse prognostic predictive value of intensive MGMT staining.

keywords:

The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study

I-Wei Chang , Chao-Tien Hsu , Jui-Wei Lin , Chih-Hsin Hung

ganglioglioma, low-grade, MGMT, O6-methylguanine-DNA methyltransferase, WHO grade I

I-Wei Chang

,

Chao-Tien Hsu

,

Jui-Wei Lin

,

Chih-Hsin Hung